Eisenberger, Mario A.

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 5,735

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 2,710

A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma

Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 1,464

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 1,145

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., et al. (1998) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 859

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Halabi, S., Kelly, W. K., Ma, H., Zhou, H., Solomon, N. C., Fizazi, K., Tangen, C. M., Rosenthal, M., Petrylak, D. P., Hussain, M., et al. (2016) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 461

The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer

Pond, G. R., Sonpavde, G., de Wit, R., Eisenberger, M. A., Tannock, I. F., & Armstrong, A. J. (2014) · European Urology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 193

Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer

Deek, M. P., Taparra, K., Phillips, R., Velho, P. I., Gao, R. W., Deville, C., Song, D. Y., Greco, S., Carducci, M., Eisenberger, M., et al. (2021) · European Urology Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 96

Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma: A Southwest Oncology Group study

Marshall, M. E., Wolf, M. K., Crawford, E. D., Taylor, S., Blumenstein, B., Flanigan, R., Meyers, F. J., Hynes, H. E., Barlogie, B., & Eisenberger, M. (1993) · Investigational New Drugs

Renal cell carcinoma treatmentBladder and Urothelial Cancer Treatments

Cited by 24

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer

McHugh, D., Eisenberger, M., Heath, E. I., Bruce, J., Danila, D. C., Rathkopf, D. E., Feldman, J., Slovin, S. F., Anand, B., Chu, R., et al. (2019) · Investigational New Drugs

Prostate Cancer Treatment and ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 23